BBOT vs EXEL
BBOT: BridgeBio Oncology is advancing next-generation small-molecule inhibitors of RAS and PI3K pathways for previously untreatable solid tumors including KRAS-driven lung and pancreatic cancers. EXEL: Exelixis is a profitable oncology company commercializing the multi-kinase inhibitor cabozantinib across multiple cancer indications while advancing a pipeline of next-generation small molecules and antibody-drug conjugates.
Side-by-side fundamentals
| Metric | BBOT | EXEL | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $8.90 | $54.98 | |
| Market cap as of 2026-07-23 | $701M | $14.0B | |
| P/E as of 2026-07-23 | 148.50 | 16.74 | EXEL lower |
| PEG as of 2026-07-23 | n/a | 1.09 | |
| Net margin as of 2026-07-23 | n/a | +35.1% | |
| Gross margin as of 2026-07-23 | n/a | +96.4% | |
| Operating margin as of 2026-07-23 | n/a | +39.4% | |
| ROE as of 2026-07-23 | +2.5% | +40.2% | EXEL higher |
| ROA as of 2026-07-23 | +2.4% | +30.5% | EXEL higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +7.9% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +9.5% | |
| Beta as of 2026-07-23 | 0.82 | 0.41 | |
| 1-year return as of 2026-07-22 close | -18.7% | +26.8% | EXEL higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.